Payment overview · 2025
General Payments
$164.61
4 reported records · 4 companies
Healthcare provider profile · identity verified
Stanley Melvin Hatesohl, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS VILLAGE, AR · NPI 1396793741
Verified facts
What the public records show
CMS Open Payments records show Stanley Melvin Hatesohl, M.D. received $164.61 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $113.51 | 69.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.40 | 11.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.32 | 10.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.38 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $164.61 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.51 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 731 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 579 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 131 |
| Lisinopril | Lisinopril | 397 | 133 |
| Omeprazole | Omeprazole | 361 | 106 |
| Losartan Potassium | Losartan Potassium | 346 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 319 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 290 | 99 |
| Trazodone Hcl | Trazodone Hcl | 283 | 86 |
| Gabapentin | Gabapentin | 251 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 246 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 78 |
| Famotidine | Famotidine | 209 | 72 |
| Metformin Hcl Er | Metformin Hcl | 207 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 201 | 58 |
| Simvastatin | Simvastatin | 176 | 55 |
| Metformin Hcl | Metformin Hcl | 172 | 55 |
| Sertraline Hcl | Sertraline Hcl | 159 | 47 |
| Meloxicam | Meloxicam | 141 | 53 |
| Furosemide | Furosemide | 140 | 55 |
| Tramadol Hcl | Tramadol Hcl | 138 | 40 |
| Potassium Chloride | Potassium Chloride | 135 | 48 |
| Allopurinol | Allopurinol | 132 | 40 |
| Donepezil Hcl | Donepezil Hcl | 124 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 36 |
| Carvedilol | Carvedilol | 113 | 32 |
| Memantine Hcl | Memantine Hcl | 112 | 29 |
| Glipizide Er | Glipizide | 111 | 34 |
| Finasteride | Finasteride | 107 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 56 |
| Atenolol | Atenolol | 101 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 33 |
| Montelukast Sodium | Montelukast Sodium | 96 | 29 |
| Eliquis | Apixaban | 91 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 30 |
| Bupropion Xl | Bupropion Hcl | 80 | 23 |
| Prednisone | Prednisone | 78 | 66 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 22 |
| Ozempic | Semaglutide | 77 | 19 |
| Warfarin Sodium | Warfarin Sodium | 76 | 14 |
| Alprazolam | Alprazolam | 75 | 26 |
| Glimepiride | Glimepiride | 69 | 16 |
| Spironolactone | Spironolactone | 68 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 66 | 18 |
| Lorazepam | Lorazepam | 65 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 23 |
| Mounjaro | Tirzepatide | 62 | 14 |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Buspirone Hcl | Buspirone Hcl | 57 | 14 |
| Celecoxib | Celecoxib | 56 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 21 |
| Ramipril | Ramipril | 54 | 18 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 14 |
| Valsartan | Valsartan | 49 | 16 |
| Xarelto | Rivaroxaban | 48 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 12 |
| Myrbetriq | Mirabegron | 42 | 11 |
| Fenofibrate | Fenofibrate | 40 | 13 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 16 |
| Lovastatin | Lovastatin | 39 | 12 |
| Primidone | Primidone | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 29 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 13 |
| Temazepam | Temazepam | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Estradiol | Estradiol | 25 | 14 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 15 |
| Anastrozole | Anastrozole | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 21 |
| Dutasteride | Dutasteride | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Glipizide | Glipizide | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $164.61 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, JOURNAVX, OTEZLA, Ozempic, REPATHA, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error